Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Consolidation in HGBL (HO152)
NCT03620578Phase 2Active, not recruiting
- Sponsor
- HOVON
- Start
- Aug 2018
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in high grade B-cell lymphoma (HGBCL), sponsored by HOVON. Primary endpoint: Disease-Free Survival at 12 months. Started Aug 2018; status: active, not recruiting.
02
Drugs
03
Conditions
high grade B-cell lymphoma (HGBCL)
Beyond the preview
Go deeper on NCT03620578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03620578.